A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia
Pharmacology, Toxicology and Pharmaceutical Science
4
10%
Biochemistry, Genetics and Molecular Biology
4
10%
Agricultural and Biological Sciences
3
7%
Nursing and Health Professions
2
5%
Other
2
5%
Unknown
12
29%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2025.
All research outputs
#5,147,191
of 34,410,315 outputs
Outputs from Cancer (0008543X)
#4,563
of 18,989 outputs
Outputs of similar age
#21,997
of 154,353 outputs
Outputs of similar age from Cancer (0008543X)
#38
of 170 outputs
Altmetric has tracked 34,410,315 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 18,989 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,353 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 170 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
